News
IFRX
2.610
+5.67%
0.140
Weekly Report: what happened at IFRX last week (0511-0515)?
Weekly Report · 5d ago
InflaRx Raised to Strong Buy From Outperform by Raymond James
Dow Jones · 05/13 18:03
InflaRx Price Target Raised to $9.00/Share From $7.00 by Raymond James
Dow Jones · 05/13 18:03
Raymond James Upgrades InflaRx to Strong Buy, Raises Price Target to $9
Benzinga · 05/13 17:53
InflaRx upgraded to Strong Buy from Outperform at Raymond James
TipRanks · 05/13 12:32
InflaRx price target raised to $8 from $6 at H.C. Wainwright
TipRanks · 05/11 18:30
InflaRx Price Target Raised to $8.00/Share From $6.00 by HC Wainwright & Co.
Dow Jones · 05/11 17:42
InflaRx Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 05/11 17:42
HC Wainwright & Co. Maintains Buy on InflaRx, Raises Price Target to $8
Benzinga · 05/11 17:36
InflaRx Price Target Raised to $4.00/Share From $2.00 by Cantor Fitzgerald
Dow Jones · 05/11 13:57
InflaRx Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 05/11 13:57
Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $4
Benzinga · 05/11 13:47
Cantor Fitzgerald Remains a Buy on InflaRx (IFRX)
TipRanks · 05/11 12:31
Guggenheim Sticks to Its Buy Rating for InflaRx (IFRX)
TipRanks · 05/11 11:46
Weekly Report: what happened at IFRX last week (0504-0508)?
Weekly Report · 05/11 09:12
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 05/08 21:06
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
Barchart · 05/08 07:15
InflaRx Raises $150 Million in Underwritten Share Offering Filed in Early May 2026
TipRanks · 05/07 20:40
InflaRx to develop izicopan in AAV
TipRanks · 05/07 03:51
InflaRx Q1 2026 Earnings Preview
Seeking Alpha · 05/06 17:25
More
Webull provides a variety of real-time IFRX stock news. You can receive the latest news about Inflarx through multiple platforms. This information may help you make smarter investment decisions.
About IFRX
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.